FSTL1 antibody
- Known as:
- FSTL1 (anti-)
- Catalog number:
- orb100642
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Biorbyt biorb
- Gene target:
- FSTL1 antibody
Related genes to: FSTL1 antibody
- Gene:
- FSTL1 NIH gene
- Name:
- follistatin like 1
- Previous symbol:
- -
- Synonyms:
- FRP, FSL1, OCC1, OCC-1, tsc36
- Chromosome:
- 3q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1999-09-07
- Date modifiied:
- 2016-06-09
Related products to: FSTL1 antibody
Related articles to: FSTL1 antibody
- Hydrocephalus comprises etiologically heterogeneous disorders that converge on ventricular enlargement but may be associated with distinct protein-abundance patterns within the cerebrospinal fluid (CSF) compartment. This exploratory study compared CSF proteomic profiles in post-hemorrhagic hydrocephalus (PHH) and idiopathic normal pressure hydrocephalus (iNPH) to characterize CSF protein-abundance patterns associated with these two hydrocephalus and identify proteins for further validation. - Source: PubMed
Publication date: 2026/05/29
Han HaoXie XunXie MingchenZhang YahuiCheng JianhuaXu Jian - - Source: PubMed
Publication date: 2026/05/25
Duan JiaoniuZhang GailianZhang Liyun - - Source: PubMed
Publication date: 2026/05/01
Kolla Sasi KumarBandi Velangani Divya Vardhan KumarMeda Raviteja - Mapping the protein-binding landscape of doxorubicin (DOX) is pivotal for optimizing therapeutic efficacy and overcoming resistance. In this study, we integrated data from prior protein microarray screenings that identified 363 DOX-binding proteins (with a signal-to-noise ratio (SNR) > 4) along with 224 Homo sapiens expression profiling series obtained from the Gene Expression Omnibus (GEO). Cross-analysis indicated that follistatin-like 1 (FSTL1) consistently demonstrated bidirectional expression across three GEO series (GSE202536, GSE13477, GSE155478), indicating sensitivity to DOX. Specifically, FSTL1 expression was suppressed in resistant cell lines (CAL-51/DOX, MCF-7/DOX) and restored after DOX treatment in their sensitive parental counterparts. Protein microarray analysis confirmed a strong interaction (SNR = 5.763), which was further corroborated by surface plasmon resonance (SPR) assays, indicating micromolar affinity. AlphaFold3 modeling combined with docking and 400 ns molecular dynamics simulations demonstrated that hydrophobic interactions and hydrogen bonding stabilize the FSTL1-DOX complex. TCGA-BRCA analysis revealed decreased FSTL1 expression in tumor tissues, modest diagnostic discrimination between tumor and normal samples (AUC = 0.76), and improved overall survival among patients with elevated FSTL1 expression. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses notably associated FSTL1 with extracellular matrix organization and the PI3K-Akt signaling pathway, supporting its potential relevance as a biomarker candidate and mechanistic hypothesis for anthracycline responsiveness. - Source: PubMed
Publication date: 2026/06/03
Wang WentaoLi SenCai YanfeiChen YunZhu JingyuJin Jian - Head and neck squamous cell carcinoma (SCC) has many subtypes, including basaloid (BSCC) and adenosquamous carcinoma (ASC). We describe a surface-derived carcinoma with features of both BSCC and ASC, along with frequent myoepithelial differentiation. Five cases were retrieved, slides were reviewed and results tabulated. DNA- and RNA-sequencing were performed in 4 and 5 cases, respectively. Patients were 4 men and 1 woman, from 55 to 78 years (mean, 68.6). Sites of origin were 2 hypopharynx, 2 oral cavity and 1 oropharynx. All cases demonstrated basaloid morphology and duct formation. Squamous dysplasia was in the overlying epithelium in 4 of 5. The tumors showed marked pleomorphism, mitotic activity, and necrosis. By immunohistochemistry, the tumors demonstrated non-diffuse p40/p63 expression sparing ducts. SOX10 and S100 were positive to varying extents in all, while SMA/SMMS was positive in 4 of 5. MYB IHC/RNA ISH were positive in all cases. Neuroendocrine markers were negative. Sequencing demonstrated SCC-like genetics with TP53 mutations (4 of 4), 11q13 amplification (3 of 4), and structural variants of unknown significance in 2 of 5 (Case 4 GLI3::ZNF804B, Case 5 ZNF521::AC090403.1 and CYLD::FSTL1). We demonstrate SCCs with basaloid features, non-diffuse p40/p63, as well as ductal and often myoepithelial differentiation. Despite features which traditionally point to a salivary-type carcinoma, especially high-grade AdCC, they exhibited squamous dysplasia/conventional SCC, SCC-like mutational profiles, and absence of MYB/MYBL1/NFIB fusions, strongly supporting squamous derivation. We propose the term basaloid ASC mimicking AdCC (BAC MAC). Recognition of this new SCC variant is important to avoid misdiagnosis and mismanagement. - Source: PubMed
Publication date: 2026/06/02
Berger BlainePalsgrove DoreenTillman BrittnyWakely PaulXu JingBishop Justin A